Adverum Biotechnologies

Adverum Biotechnologies is a company focused on developing gene therapies to treat debilitating ocular diseases. Their mission is to establish gene therapy as a new standard of care, particularly in treating conditions like wet age-related macular degeneration (wet AMD), which is a leading cause of blindness globally. The company is advancing their investigational gene therapy Ixo-vec, designed to provide a long-lasting treatment through a single in-office administration, which could replace the current standard of frequent and painful eye injections. By leveraging their proprietary adeno-associated virus (AAV) vector platform, Adverum aims to transform the standard of care, improve accessibility to treatment, and achieve significant societal impact by restoring vision and preventing blindness.